Reviewing Verastem Inc. (VSTM)’s and OPKO Health Inc. (NASDAQ:OPK)’s results

This is therefore a contrasting of the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation in Verastem Inc. (NASDAQ:VSTM) and OPKO Health Inc. (NASDAQ:OPK). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Verastem Inc. 26.72M 8.60 72.43M -1.44 0.00
OPKO Health Inc. 990.27M 1.56 153.04M -0.52 0.00

Demonstrates Verastem Inc. and OPKO Health Inc. earnings per share, top-line revenue and valuation.


Table 2 shows us the net margins, return on assets and return on equity of both companies.

Net Margins Return on Equity Return on Assets
Verastem Inc. -271.07% -95.9% -61.7%
OPKO Health Inc. -15.45% -16.4% -11.8%

Risk & Volatility

Verastem Inc. is 205.00% more volatile than Standard & Poor’s 500 because the stock has a beta of 3.05. Competitively, OPKO Health Inc. is 89.00% more volatile than Standard & Poor’s 500, because of the 1.89 beta.


The Current Ratio of Verastem Inc. is 3 while its Quick Ratio stands at 3. The Current Ratio of rival OPKO Health Inc. is 0.9 and its Quick Ratio is has 0.8. Verastem Inc. is better equipped to clear short and long-term obligations than OPKO Health Inc.

Analyst Recommendations

Verastem Inc. and OPKO Health Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Verastem Inc. 0 0 3 3.00
OPKO Health Inc. 0 0 0 0.00

$10 is Verastem Inc.’s average target price while its potential upside is 221.54%.

Insider and Institutional Ownership

Verastem Inc. and OPKO Health Inc. has shares owned by institutional investors as follows: 61.5% and 24.9%. About 0.6% of Verastem Inc.’s share are owned by insiders. Comparatively, OPKO Health Inc. has 5.7% of it’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Verastem Inc. -6.71% -6.71% -39.88% -68.31% 0.33% -8.93%
OPKO Health Inc. -5.99% -27.45% -22.83% -54.36% -29.74% -11.3%

For the past year Verastem Inc. has stronger performance than OPKO Health Inc.


On 6 of the 11 factors OPKO Health Inc. beats Verastem Inc.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The companyÂ’s defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. The companyÂ’s duvelisib is in Phase 3 randomized and two-arm trial for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with refractory indolent non-Hodgkin lymphoma. The company has license agreement with Infinity Pharmaceuticals, Inc.; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companyÂ’s Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companyÂ’s pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.